SC
OVID icon

Stempoint Capital’s Ovid Therapeutics OVID Stock Holding History

Stempoint Capital’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.5M Buy
+2,417,283
New +$6.24M 1.12% 29

Other funds holding OVID

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Stempoint Capital's OVID Position: Q2 2026 in Review

Stempoint Capital opened a new position in Ovid Therapeutics (OVID) in Q2 2026: 2,417,283 shares worth $6.5M. The stake represents 1.12% of the portfolio and ranks #29 among its holdings.

93 funds tracked by Wall St. Rank hold OVID as of Q2 2026.

  • Stempoint Capital held 2,417,283 shares of Ovid Therapeutics worth $6.5M as of Q2 2026.
  • Ovid Therapeutics was a new Stempoint Capital position in Q2 2026.
  • Ovid Therapeutics made up 1.12% of Stempoint Capital's portfolio in Q2 2026, its #29 holding.
  • 93 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q2 2026.

Based on Stempoint Capital's 13F filing for Q2 2026, filed 14 Aug 2026.